The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.

Autor: Gómez Rueda A; Medical Oncology Department, IRYCIS, Hospital Universitario Ramón y Cajal, Carretera Colmenar ViejoKM 9100, 28034, Madrid, Spain., Taus Á; Medical Oncology Department, Hospital del Mar, Barcelona, Spain., Álvarez Álvarez R; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain., Bernabé-Caro R; Medical Oncology Department, Hospital Virgen del Rocío, Seville, Spain., Chara L; Medical Oncology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain., López-Brea M; Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain., Vilà L; Medical Oncology Department, Hospital Universitario Parc Taulí, Institut d'Investigació I Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Sabadell, Spain., Sala González MÁ; OSI Bilbao Basurto, Bibao, Spain., Del Barrio Díaz Aldagalán A; HM Sanchinarro, Madrid, Spain., Esteban Herrera B; Hospital General de Segovia, Segovia, Spain., López Castro R; Hospital Clínico Universitario de Valladolid, Valladolid, Spain., Álvarez Cabellos R; Medical Oncology Service, Hospital Universitario de Toledo, Toledo, Spain., Doménech M; Medical Oncology Department, Instituto Catalán de Oncología, Badalona, Spain.; Hospital Germans Trias i Pujol, Barcelona, Spain., Falagan S; Hospital Universitario Infanta Sofía, Madrid, Spain., Moreno Vega A; Hospital Universitario Reina Sofía, Córdoba, Spain., Aguado C; Medical Oncology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain., Barba A; Medical Oncology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain., Delgado Ureña MT; Medical Oncology Department, Hospital Clínico San Cecilio, Granada, Spain., Isla D; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain., Bellido Hernández L; Medical Oncology Department, Hospital Universitario de Salamanca, Salamanca, Spain., Fírvida Pérez JL; Complejo Hospitalario Universitario de Ourense, Ourense, Spain., Juan-Vidal Ó; Medical Oncology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain., Massutí B; Medical Oncology Department, Hospital Universitario de Alicante-ISABIAL, Alicante, Spain., Mielgo-Rubio X; Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain., Ortega AL; UGC de Oncología Médica, Hospital Universitario de Jaén, Jaén, Spain., Catot S; Medical Oncology Department Althaia, Xarxa Assistencial Universitària Manresa, Barcelona, Spain., Dómine M; Hospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain., Escoín-Pérez C; Medical Oncology Department, Hospital Universitario de La Ribera, Valencia, Spain., García Navalón F; Medical Oncology Department, Hospital Universitario Son Llatzer, Mallorca, Spain., Gil-Bazo I; Medical Oncology Department, Clínica Universidad de Navarra, Pamplona, Spain.; Fundación Instituto Valenciano de Oncología, Valencia, CIBERONC, Madrid, Spain., Muñoz S; Medical Oncology Department, Hospital General de Granollers, Barcelona, Spain., Rodríguez-Abreu D; Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain., Villatoro Roldán RM; Medical Oncology Department, Hospital Costa del Sol, Málaga, Spain., Alonso-Jáudenes Curbera G; Medical Oncology Department, Complejo Hospitalario Universitario de A Coruña, Coruña, Spain., León-Mateos L; Medical Oncology Department, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Instituto de Investigación Sanitaria (IDIS), Santiago de Compostela, Spain., Padilla A; Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain., Paredes Lario A; Department of Medical Oncology, Hospital Universitario de Donostia, San Sebastián, Spain., Sánchez-Torres JM; Department of Medical Oncology, Hospital Universitario la Princesa, Madrid, Spain., Garrido P; Medical Oncology Department, IRYCIS, Hospital Universitario Ramón y Cajal, Carretera Colmenar ViejoKM 9100, 28034, Madrid, Spain. pilargarridol@gmail.com.

Publikováno v: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 Jul; Vol. 26 (7), pp. 1779-1789. Date of Electronic Publication: 2024 Mar 21.

Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study).

Autor: Aguado de la Rosa C; Department of Medical Oncology, Hospital Clínico San Carlos, Madrid, Spain., Cruz Castellanos P; Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain., Lázaro-Quintela M; Department of Medical Oncology, Hospital Alvaro Cunqueiro, Vigo, Spain., Dómine M; Department of Medical Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain., Vázquez Estévez S; Department of Medical Oncology, Hospital Universitario Lucus Augusti, Lugo, Spain., López-Vivanco G; Department of Medical Oncology, Hospital Universitario de Cruces, Baracaldo, Spain., Fírvida Pérez JL; Department of Medical Oncology, Complejo Hospitalario Universitario de Ourense, Ourense, Spain., Alonso Romero JL; Department of Medical Oncology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, IMIB-Arrixaca, Spain., Ferrera Delgado L; Department of Medical Oncology, Hospital Universitario de La Candelaria, Santa Cruz de Tenerife, Spain., García Girón C; Department of Medical Oncology, Hospital Universitario de Burgos, Burgos, Spain., Diz Taín P; Department of Medical Oncology, Hospital Universitario de León, León, Spain., Álvarez Álvarez R; Department of Medical Oncology, Hospital Universitario Gregorio Marañón, Madrid, Spain., Mut Sanchís P; Department of Medical Oncology, Hospital Son Llatzer, Palma de Mallorca, Spain., Fernández Cantón I; Department of Medical Oncology, Hospital Universitario de Jerez, Cádiz, Spain., Manrique Abós I; Department of Medical Oncology, Hospital San Pedro de Logroño, La Rioja, Spain., Martínez Aguillo M; Department of Medical Oncology, Hospital Universitario de Navarra, Pamplona, Spain., Gómez-Aldaraví Gutiérrez L; Department of Medical Oncology, Hospitalario Universitario de Albacete, Albacete, Spain., Ortega Granados AL; Department of Medical Oncology, Hospital Universitario de Jaén, Jaén, Spain., Álvarez Cabellos R; Department of Medical Oncology, Hospital Universitario de Toledo, Toledo, Spain., García Sebastián A; TFS Health Science at Pfizer, Madrid, Spain., García Sifuentes LF; Medical Department, Pfizer Oncology, Madrid, Spain., Reguart N; Department of Medical Oncology, Thoracic Oncology Unit, Hospital Clinic Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain. Electronic address: NREGUART@clinic.cat.

Publikováno v: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2022 Nov; Vol. 173, pp. 83-93. Date of Electronic Publication: 2022 Sep 19.

Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: a 3-month follow-up analysis.

Autor: Cobo Dols M; Medical Oncology Department, Hospital Regional Universitario de Málaga, Málaga, Spain manuelcobodols@yahoo.es., Beato Zambrano C; Medical Oncology Department, Complejo Hospitalario Virgen de la Macarena, Sevilla, Spain., Cabezón Gutiérrez L; Medical Oncology Department, Hospital Universitario de Torrejón, Torrejón de Ardoz, Spain., Chicas Sett R; Radiation Oncology Department, Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain., Blancas López-Barajas MI; Medical Oncology Department, Hospital Universitario San Cecilio, Granada, Spain., García Navalón F; Medical Oncology Department, Hospital Son Llatzer, Palma de Mallorca, Spain., Fírvida Pérez JL; Medical Oncology Department, COSAGA, Ourense, Spain., Serrano Bermúdez G; Palliative Care Service, Institut Català d' Oncologia, L'Hospitalet de Llobregat, Catalunya, Spain., Togores Torres P; Medical Oncology Department, Centro Oncológico de Galicia, La Coruña, Spain., Delgado Mingorance I; Medical Oncology Department, Hospital Universitario Infanta Cristina, Badajoz, Spain., Giraldo Marín A; Radiotherapy Oncology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain., Librán Oriol A; Cures Palliatives, Consorci Sanitari de Terrassa, Terrassa, Spain., Paredes Lario A; Medical Oncology Department, Hospital Universitario de Donostia, San Sebastián, Spain., Sánchez Mauriño P; Medical Oncology Department, Hospital Universitario Reina Sofía, Córdoba, Spain., Higuera Gómez O; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain., Moreno Muñoz D; Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain., Jiménez López AJ; Medical Department, Kyowa Kirin Farmacéutica S.L.U, Madrid, Spain., Huerta González I; Medical Department, Kyowa Kirin Farmacéutica S.L.U, Madrid, Spain., Sanz Yagüe A; Medical Department, Kyowa Kirin Farmacéutica S.L.U, Madrid, Spain., Soler López B; Medical Department, E-C-BIO, S.L, Las Rozas, Spain.

Publikováno v: BMJ supportive & palliative care [BMJ Support Palliat Care] 2021 Mar; Vol. 11 (1), pp. 25-31. Date of Electronic Publication: 2020 May 06.

Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy.

Autor: Ruiz-Bañobre J; Medical Oncology Department, Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain.; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago de Compostela, CIBERONC, Santiago de Compostela, Spain., Areses-Manrique MC; Medical Oncology Department, Complejo Hospitalario Universitario de Ourense, Ourense, Spain., Mosquera-Martínez J; Medical Oncology Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain., Cortegoso A; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago de Compostela, CIBERONC, Santiago de Compostela, Spain.; Medical Oncology Department, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain., Afonso-Afonso FJ; Medical Oncology Department, Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain., de Dios-Álvarez N; Medical Oncology Department, Complejo Hospitalario Universitario de Vigo, Vigo, Spain., Fernández-Núñez N; Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain., Azpitarte-Raposeiras C; Medical Oncology Department, Complejo Hospitalario de Pontevedra, Pontevedra, Spain., Amenedo M; Medical Oncology Department, Centro Oncológico de Galicia, A Coruña, Spain., Santomé L; Medical Oncology Department, Hospital Povisa, Vigo, Spain., Fírvida-Pérez JL; Medical Oncology Department, Complejo Hospitalario Universitario de Ourense, Ourense, Spain., García-Campelo R; Medical Oncology Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain., García-González J; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago de Compostela, CIBERONC, Santiago de Compostela, Spain.; Medical Oncology Department, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain., Casal-Rubio J; Medical Oncology Department, Complejo Hospitalario Universitario de Vigo, Vigo, Spain., Vázquez S; Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain.

Publikováno v: Translational lung cancer research [Transl Lung Cancer Res] 2019 Dec; Vol. 8 (6), pp. 1078-1085.

Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience.

Autor: Areses Manrique MC; Complejo Hospitalario Universitario de Ourense, Ourense, Spain., Mosquera Martínez J; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain., García González J; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coruña, Spain., Afonso Afonso FJ; Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain., Lázaro Quintela M; Complejo Hospitalario Universitario de Vigo, Vigo, Spain., Fernández Núñez N; Hospital Universitario Lucus Augusti, Lugo, Spain., Azpitarte Raposeiras C; Complejo Hospitalario de Pontevedra, Pontevedra, Spain., Amenedo Gancedo M; Centro Oncológico de A Coruña, A Coruña, Spain., Santomé Couto L; Hospital Povisa, Vigo, Spain., García Campelo MR; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain., Muñoz Iglesias J; Complejo Hospitalario Universitario de Ourense, Ourense, Spain., Cortegoso Mosquera A; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coruña, Spain., Vilchez Simo R; Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain., Casal Rubio J; Complejo Hospitalario Universitario de Vigo, Vigo, Spain., Campos Balea B; Hospital Universitario Lucus Augusti, Lugo, Spain., Carou Frieiro I; Complejo Hospitalario de Pontevedra, Pontevedra, Spain., Alonso-Jaudenes Curbera G; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain., Anido Herranz U; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coruña, Spain., García Mata J; Complejo Hospitalario Universitario de Ourense, Ourense, Spain., Fírvida Pérez JL; Complejo Hospitalario Universitario de Ourense, Ourense, Spain.

Publikováno v: Translational lung cancer research [Transl Lung Cancer Res] 2018 Jun; Vol. 7 (3), pp. 404-415.